Mesenchymal stem cells (MSC) represent a promising therapeutic approach in many diseases in view of their potent immunomodulatory properties, which are only partially understood. Here, we show that the endothelium is a specific and key target of MSC during immunity and inflammation. In mice, MSC inhibit activation and proliferation of endothelial cells in remote inflamed lymph nodes (LNs), affect elongation and arborization of high endothelial venules (HEVs) and inhibit T-cell homing. The proteomic analysis of the MSC secretome identified the tissue inhibitor of metalloproteinase-1 (TIMP-1) as a potential effector molecule responsible for the anti-angiogenic properties of MSC. Both in vitro and in vivo, TIMP-1 activity is responsible for the antiangiogenic effects of MSC, and increasing TIMP-1 concentrations delivered by an Adeno Associated Virus (AAV) vector recapitulates the effects of MSC transplantation on draining LNs. Thus, this study discovers a new and highly efficient general mechanism through which MSC tune down immunity and inflammation, identifies TIMP-1 as a novel biomarker of MSC-based therapy and opens the gate to new therapeutic approaches of inflammatory diseases.
INTRODUCTION
Mesenchymal stem cells (MSC) are multipotent progenitor cells with self-renewable capacity and the potential to differentiate into various mesodermal lineages. 1 MSC are present in the stromal fraction of many tissues, where they reside close to blood vessels, 2 a trait that is shared with pericytes. Indeed, when analyzed in vitro, MSC and pericytes display similar morphological and functional features, although the two cell types are likely to have different functions in vivo. 3 Although pericytes regulate capillary homeostasis and architecture, 4 the in vivo functional role of MSC is less clear and it is likely to be tissue-specific. For example, in the bone marrow, MSC contribute to the formation of the 'niche' for the hematopoietic stem cells (HSC), thus providing an appropriate microenvironment for hematopoiesis. 5 In other tissues, MSC may be involved in homeostatic control and tissue repair. 6 A well-established feature of MSC is their ability to inhibit inflammation and immunity, both in vitro and in vivo. In mouse models of human diseases, MSC have been shown to be highly immunosuppressive being effective, for example, in the treatment of experimental autoimmune encephalomyelitis, 7 collageninduced arthritis 8 or graft-versus-host disease. 9 On the basis of these experimental results, MSC are now used in several clinical trials (see www.clinical trials.gov) and represent a new frontier in cellular therapy. The anti-inflammatory effect of MSC can be largely explained by their ability to secrete a vast array of soluble mediators with immunomodulatory properties, such as interleukin-10 (IL-10), prostaglandin E2, transforming growth factor, nitric oxide (for mouse MSC) and indoleamine-2,3-dioxygenase (for human MSC), and tumor necrosis factor-α (TNF-α)-stimulated protein 6 (ref. [9] [10] [11] that may act in a paracrine or endocrine manner. However, a unifying mechanism of action is still missing, and it is likely that other specific mediators and targets explaining the in vivo immunosuppressive effects of MSC remain to be identified.
Both inflammatory and immune responses depend on migration of leukocytes. Recruitment of neutrophils and monocytes into inflamed tissues is directed by chemokines induced by inflammatory stimuli, including bacterial lipopolysaccharide, IL-1 and TNF-α. 12, 13 On the other hand, adaptive immunity starts in secondary lymphoid organs, where naive antigen-specific T cells encounter dendritic cells loaded with cognate antigen. For this to occur, T cells must enter lymph nodes (LNs) via specialized postcapillary venules that are made up of endothelial cells with cuboidal morphology and therefore called high endothelial venules (HEVs). 14, 15 Endothelial cells have a major role in these processes, changing their phenotypes to support various phases of the inflammatory responses. The capacity of leukocytes to interact with the endothelium is determined by the activation of 1 endothelial cells that in turn leads to the expression of a variety of chemoattractants and surface adhesion molecules including intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). 16 In addition, if the inflammatory stimulus persists, then angiogenesis is initiated by the migration of endothelial cells lining the venules into the tissue. 16, 17 The generation of new blood vessels is required for the survival of inflammatory cells within the tissue, and thus inhibition of factors that promote angiogenesis may reduce inflammation and prevent its pathological consequences such as inflammatory tissue damage, autoimmunity, fibrosis or tumor growth. 16, 18 In this study, we have identified the endothelium as a specific and novel target of MSC-based therapy. 
MATERIALS AND METHODS

Immunization with Complete Freund Adjuvant/Ovalbumin
In all, 1 mg/ml Ovalbumin (OVA) (Sigma-Aldrich, Steinheim, Germany) was emulsified in Complete Freund Adjuvant (CFA) (Sigma-Aldrich), and 100 μl of emulsion was injected subcutaneously (s.c.) in three sites in the back. After 24 h, 1 × 10 6 MSC were injected s.c. in the lumbar region. Immunized mice were killed 4 days later, and the brachial draining LNs (dLNs) were collected and frozen in OCT for immunofluorescence or digested for FACS analysis.
In vivo tissue inhibitor of metalloproteinase-1 immunoneutralization
Goat polyclonal anti-TIMP-1 IgG 19 (catalog no. AF980; R&D Systems, Minneapolis, MN, USA) was intravenously (i.v.) administered (0.5 mg/kg) in immunized mice 18 h after MSC transplantation. As a control, additional mice were given equivalent doses of an isotype-matched goat IgG (catalog no. AB-108-C, R&D Systems). Immunized mice were killed 2 days later, and the brachial dLNs were collected and digested for endothelial cell analysis by FACS. Data are representative of 36 LNs/group analyzed from four independent experiments.
Tissue inhibitor of metalloproteinase-1 siRNA reverse transfection AAV-mediated TIMP-1 overexpression All the AAV vectors used in this study were generated by the AAV Vector Unit (AVU) at ICGEB Trieste (http://www.icgeb.org/avu-core-facility.html) as described previously. 20 Briefly, AAV vectors of serotype 9 were produced in HEK293T cells, using a triple plasmid co-transfection method. Viral stocks were collected after CsCl 2 gradient centrifugation. The total number of viral genome was determined by real-time PCR; the viral preparations had titers between 1 × 10 13 and 3 × 10 13 viral genome (vg) particles per ml. AAV9-TIMP-1 was intraperitoneally injected at a dose of 2 × 10 11 vg in 100 μl PBS − / − . Equal amount of AAV9-LacZ was used as a control. One day after AAV9 administration, mice were immunized with CFA/OVA as discussed above (6 mice 
Optical projection tomography
In all, 5 μg of Alexa-594 MECA-79 antibody (conjugated according to the manufacturer's instructions using the Alexa-594 conjugation kit; Invitrogen) was injected i.v. 15 min before organ harvest. Brachial LNs were excised, cleaned of surrounding fat and then incubated with AlexaFluor 488-conjugated anti-B220 (0.67 μg/ml) as previously described. 21 Further details are described in the Supplementary methods.
3D immunofluorescence
Mice were immunized and transplanted as described above. On day 3 after immunization, single-cell suspensions were obtained from LNs of C57/Bl6 wt mice. CD4 + T cells were isolated using the mouse CD4 + T cell isolation kit (Stem Cell Technologies, Vancouver, BC, Canada), according to the manufacturer's protocol. The lymphocytes were fluorescently labelled, injected i.v. into CFA/OVA immunized recipient mice and allowed to home for 20 min before blocking further homing with anti-L-selectin mAb. After 20 min, dLNs were isolated, treated and analyzed as previously described. 22 Data are representative of eight (CFA/OVA) and nine (+MSC) mice from three independent experiments.
Cryo imaging MSC labelled with qTracker 655 (Life Technologies, Oslo, Norway) were s.c. injected into a control mouse or a mouse previously immunized with CFA/ LN angiogenesis is a direct target of MSC transplantation L Zanotti et al OVA. Mice were killed 4 days later, frozen and cryo-imaged using the CryoViz cryo-imaging system (BioInVision, Inc., Cleveland, OH, USA) as described in Roy et al. 23, 24 Cryo-images were acquired using the ProSCI software as described in Roy et al. 24 Further details are described in the Supplementary methods.
Statistical analysis
The sample size per group was estimated from previous experience with similar experiments. There were no pre-established criteria for mice or sample exclusion: except evident technical damage. Data were collected and analysis was done without the investigator knowing group allocation. Data were analyzed using the Prism Software (GraphPad, La Jolla, CA, USA). Data were expressed as mean ± s.e. Differences were assessed using t-test, Mann-Whitney test or one-way ANOVA. Statistic tests were performed between data with similar variance. Results with a P-value of o0.05 were considered as significant.
RESULTS
MSC transplantation affects endothelial activation in immune reactive LNs
We have previously shown that encapsulated MSC injected s.c. are able to control systemic and local inflammation through the release of soluble factors. 9 Moreover, we have demonstrated that subcutaneous administration of MSC is more efficient than the intravenous route, probably because most of the MSC injected i.v. are trapped in the lungs and cleared after a few days. 9, [25] [26] [27] On the basis of our previous data indicating that encapsulation was not required to improve the efficacy of s.c. injected MSC, 9 in this study we performed subcutaneous injections of free MSC (not encapsulated) in the lumbar area of mice that had been previously immunized with OVA in CFA (CFA/OVA) in the upper dorsal region. As expected, the immunization induced a robust and rapid response in the brachial dLNs ( Figure 1 ). MSC transplantation significantly reduced this response, decreasing both the total cellularity and the volume of dLNs and affecting the recruitment of specific cell populations (Figures 1b-e), as already described. 9 Using whole-mouse cryo-imaging analysis, 28 we verified that s.c. injected MSC did not migrate away from the site of injection during the experimental time (5 days), both in immunized and in untreated mice (Supplementary Movies S1 and S2). Together with our previous study, 9 these data indicate that MSC are able to dampen inflammation through the release of soluble mediators.
LN growth during immune responses is accompanied by endothelial activation and vascular expansion, two events that are required for leukocytes recruitment and orchestration of immunity. We analyzed the expression of two adhesion molecules, VCAM-1 and ICAM-1, that are typically upregulated on the inflamed endothelium (Figures 2a-d) . Interestingly, the dLN vessels of mice treated with MSC had a lower expression of both VCAM-1 and ICAM-1, as demonstrated by the colocalization analysis expressed as Mander's coefficient (Figures 2b-d) . Moreover, we observed that the dLNs of mice transplanted with MSC showed reduced density of the endothelial marker CD31 and of Lyve-1, a marker of the lymphatic endothelium, suggesting a reduced vascular expansion upon MSC treatment (Figures 2a, c and e).
Altogether, these data indicate that MSC inhibit activation of vascular and lymphatic endothelium in the dLNs of immunized mice.
MSC inhibit activation and elongation of HEVs and affect recruitment of T cells to dLNs
The migration of leukocytes from the blood stream into LNs occurs via HEVs, which are post-capillary venules structurally adapted to support lymphocyte trafficking. Because of the reduced numbers of leukocytes present in the dLNs of mice treated with MSC ( Figure 1 ), 9 we asked whether MSC transplantation affects HEV activation, lymph-node vascularization and leukocyte migration in vivo.
MSC were s.c. injected in the lumbar region of mice that had been previously immunized in the dorsal region with CFA/OVA, as already described (Figure 1 Analysis of entire LNs by optical projection tomography, which allows a three-dimensional reconstruction of the HEV network, allowed us to examine the morphologic alterations that occur in HEV expansion after immunization with CFA/OVA in the presence or absence of MSC. HEVs were labelled before imaging by intravenous injection of fluorophore-tagged MECA-79, which recognizes the PNAd epitope on the luminal surface (Figure 4a , Supplementary videos S3 and S4). The HEV length was significantly impaired in mice transplanted with MSC ( Figure 4b ) and the analysis of the HEV volume suggested a tendency toward vessel narrowing, although in this case the difference did not reach statistical significance (Figure 4c ). In addition, the morphology of the HEV network was affected by MSC, as shown by the significant decrease in the number of branches and segments (Figures 4d and e) , indicating that MSC limit both HEV elongation and arborization.
The previous observation prompted us to address whether MSC impair leukocyte homing to inflamed LNs. Fluorescently labelled naive T cells were injected i.v. in mice previously immunized with CFA/OVA, and transplanted or not with MSC. After 20 min, alexa633-conjugated MECA-79 and MEL-14 mAbs were i.v. injected to stain HEV and block L-selectin, respectively, and, after 20 additional minutes, the dLNs were harvested and prepared for two-photon microscopy acquisition (Figure 4f) . 22 The analysis demonstrated that MSC transplantation inhibited T-cell homing into the inflamed LNs (Figure 4g ).
Endothelial cells are a direct target of MSC To understand whether the inhibition of endothelial cell activation and proliferation observed in immunized mice treated with MSC was due to a direct effect of MSC on endothelial cells, we analyzed the effects of MSC supernatants in various in vitro assays using a mouse vascular endothelial (1G11) and two mouse lymphatic endothelial (MELC and SVEC4-10) cell lines. [30] [31] [32] MSC were first expanded as an adherent monolayer until confluence, and were then stimulated for 24 h in the presence or absence of IL-1β, IL-6 and TNF-α to resemble the inflammatory milieu that MSC find in vivo.
33,34 MSC supernatant was collected as conditioned medium (CM) 18 h after cytokine withdrawal.
First, we analyzed the effect of MSC secretion on in vitro angiogenesis using the tube formation assay. 35 The soluble factors released by stimulated MSC strongly inhibited the ability of SVEC4-10 cells to form tube networks, whereas the medium collected from the unstimulated MSC (unst MSC-CM) had no effect (Figures 5a and b) , indicating that in an inflammatory environment MSC can directly inhibit angiogenesis. This effect was also confirmed on another lymphatic endothelial cell line (MELC; Supplementary Figure S2 ). On the basis of these results and of the published literature, 33, 34 in the following experiments we focused on the effects of the MSC-CM only.
As the in vivo data indicated that MSC transplantation affects the expression of adhesion molecules on endothelial cells (Figure 2b) , we analyzed the expression of VCAM-1 and ICAM-1 on MELC and 1G11 cells treated with 20 ng/ml TNF-α for 24 h, 30, 31 in the presence or in the absence of MSC-CM. In agreement with the previous data, the MSC-CM significantly reduced the expression of VCAM-1 and ICAM-1 on MELC (Figures 5c and e) and the expression of VCAM-1 on 1G11 cells (Figures 5d and f) .
Expression of VCAM-1 and ICAM-1 on endothelial cells is regulated by NF-kB; 36 and thus, we examined the nuclear localization of NF-kB complexes using immunofluorescence microscopy. As expected, in both MELC and 1G11 cells TNF-α stimulation resulted in prompt translocation of p65 from the cytoplasm into the nucleus. MSC-CM inhibited NF-kB translocation in both cell lines (Figures 5g-j) .
Altogether, these data indicate that endothelial cell activation is directly inhibited by soluble factors released by MSC exposed to inflammatory cytokines.
MSC inhibit in vitro angiogenesis through the release of TIMP-1
In an effort to understand the molecular mechanisms responsible for the observed effects of MSC, we performed shotgun proteomic characterization of the MSC secretome, comparing the supernatants collected from MSC stimulated (MSC-CM) or not (unst MSC-CM) with inflammatory cytokines. As detailed in Materials and methods, only proteins present and quantified in at least three out of five technical repeats, in both biological replicates, were considered as positively identified; 1613 and 1630 proteins were measured in the secretome of control and stimulated MSC, respectively.
Differential expression was considered as significant if (a) a protein was present only in MSC-CM or in control or (b) its LFQ intensity resulted statistically significant as calculated by Perseus (t-test cutoff at 1% permutation-based false discovery rate). According to this analysis, 7.6 or 8.3% of the proteins detected in the secretome of control or stimulated MSC, respectively, were differentially expressed, either upregulated or downregulated. These proteins were clustered according to their functions using the DAVID platform 37 filtered for significant Gene Ontology Biological Process (GOBP) terms using a P-value of o0.05.
Concerning the 52 proteins that were significantly downregulated or present only in the secretome of unstimulated MSC (Supplementary Table S1 ), GO analysis revealed that most terms are related to metabolic processes (Supplementary Figure S3) . As for the 89 proteins that were significantly upregulated or present only in the secretome of stimulated MSC (Supplementary Table S2 and Figure 6a ), GO analysis indicated that 18 and 30% of the proteins belong to categories that are related to regulation of angiogenesis and inflammation processes, respectively (Supplementary Table S2 and Figure 6b ). In particular, the presence of an 'angiogenesis-related' signature among upregulated proteins was also confirmed by preliminary analyses of human MSC secretome, which reveals that all the 16 upregulated proteins in stimulated MSC secretome common to human and mouse are modulators of angiogenesis (Supplementary Table S3) .
Among the several proteins upregulated in MSC by the inflammatory cytokines that have a direct or indirect effect on endothelial cells, we focused our attention on the TIMP-1 because of its well-known anti-angiogenic properties. 38 We thus used the tube formation assay to analyze the effect of MSC-derived TIMP-1 on angiogenesis. Although the blocking anti-TIMP-1 antibody had no effect on the ability of endothelial cells to form tubes when cultured in the supernatants of unstimulated MSC, it totally reverted the anti-angiogenic properties of the supernatant from stimulated MSC (Figure 7a ), indicating that, al least in this in vitro setting, TIMP-1 is one of the key MSC-secreted molecules targeting the endothelium. In an in vivo setting, the injection of neutralizing anti-TIMP-1 antibody 19 1 day after MSC transplantation reverted the MSC-induced reduction of endothelial cell numbers and HEV in dLNs (Figures 7b-d) , suggesting that TIMP-1 may be directly responsible for the anti-inflammatory effects of MSC on LNs. To confirm this hypothesis, we used a siRNA approach to knock down TIMP-1 expression in MSC (Supplementary Figure S4) . Again, the absolute cell numbers of endothelial cells and HEV in dLN were reduced by MSC transfected with the scramble siRNA control but not by MSC with TIMP-1 siRNA (Figures 7e-g ).
On the basis of these results, we speculated that overexpression of TIMP-1 might be sufficient to mimic the effects of MSC transplantation, in terms of inhibition of angiogenesis in the inflamed lymph nodes. TIMP-1 overexpression by AAV9-mediated gene transfer 20 in mice immunized with CFA/OVA (Figure 8a ) inhibited the inflammatory reaction in the draining LNs, as indicated by the reduced total cellularity (Figure 8b ), which was due to a decreased number of both CD45 + cells (Figure 8c ) and endothelial and HEV cells (Figures 8d and e) . between lymphocytes and antigen-presenting cells during both normal responses to pathogens and immune-mediated diseases, such as autoimmunity, allergy or graft-versus-host disease. 39 When a robust immune response develops, infiltrating and dividing lymphocytes markedly increase LNs cellularity, leading to organ expansion. During this swelling, there is massive endothelial cell proliferation and vascular expansion occurs. 40 Both acute and chronic inflammatory processes are indeed associated with pronounced vascular remodelling. Angiogenesis and lymph angiogenesis, the growth of new blood vessels and lymphatic vessels from pre-existing ones, are involved in a number of physiological and pathological conditions, such as wound healing, tumor growth, rheumatoid arthritis, inflammatory bowel disease and asthma. 41 Thus, the identification of therapies that specifically inhibit angiogenesis may represent a weapon to reduce inflammation and prevent disease progression. 16 Recently, it was demonstrated that MSC have a potent stabilizing effect on the vascular endothelium, having the capacity of inhibiting endothelial permeability after traumatic brain injury 42 and in hemorrhagic shock. 43 Our results demonstrate that, during In agreement with our data, homing of dendritic cell to dLNs was reduced in the presence of MSC in several mouse models 44, 45 and in vitro co-cultures of MSC with endothelial cells downregulated cytokine-induced recruitment of neutrophils and lymphocytes. 46 In our study, the effects of MSC on endothelial cell activation, HEV elongation and T-cell trafficking do not require MSC homing to LNs and are all mediated by soluble factors released by MSC. This is in agreement with another study showing an antiangiogenic activity for soluble factors present in media derived from MSC/glioma co-cultures. 47 The proteomic analysis of the MSC secretome indicated that, upon activation by inflammatory cytokines, MSC upregulate the expression of several proteins potentially affecting angiogenesis and inflammation through multiple pathways. Interestingly, when we compared the secretomes of human and mouse MSC, we found that only 16 proteins are upregulated in both cell types and 11 of them modulate angiogenesis directly or indirectly, thus supporting the idea that the endothelium is a specific target of MSC during inflammation. Notably, although many soluble factors released by cytokinetriggered MSC are positive regulators of angiogenesis, in the experimental system here described the overall in vivo effect of MSC is a reduced dLN vascular expansion.
Angiogenesis requires degradation of the vascular basement membrane and remodelling of the extracellular matrix to allow endothelial cells migration and invasion into the surrounding tissue. This process requires the action of matrix metalloproteinases (MMPs) that degrade both matrix and non-matrix proteins and have central roles in morphogenesis, wound healing, tissue repair and in progression of chronic diseases. 48 The balance between MMPs and their natural inhibitors, the TIMPs, is critical for extracellular matrix remodelling and angiogenesis. The TIMP family comprises four protease inhibitors: TIMP-1, TIMP-2, TIMP-3 and TIMP-4. With the exception of TIMP-4, 49 all three TIMPs inhibit angiogenesis in vivo, 38 although through diverse mechanisms. MSC secrete both MMPs and their inhibitors, and thus contribute to the regulation and protection of the perivascular niche. 50 Using both in vitro and in vivo assays, we identified the metalloproteinase inhibitor TIMP-1 as the molecule responsible for the anti-angiogenic effects of MSC. TIMP-1 is known to inhibit endothelial cells migration by MMP-dependent and MMPindependent mechanisms. [51] [52] [53] The latter involve regulation of various biological processes such as cell growth, apoptosis and differentiation through the CD63 receptor. 54, 55 In addition, TIMP-1 was shown to induce secretion of soluble VEGFR-1 by human endothelial cells, leading to a decrease of bioavailable VEGF and of blood vessel growth. 56 TIMP-3 has also been identified as a soluble factor produced by MSC with beneficial effects on endothelial cell function in a mouse model of traumatic brain injury; 57 however, we did not find evidence for TIMP-3 upregulation in the mouse or human MSC secretomes. It is likely that, in vivo, other soluble factors in addition to TIMP-1 contribute to MSC-mediated immune regulation: MSC are also known to produce prostaglandin E2 and thus inhibit the activation of macrophages, 58 which are a source of multiple growth factors that enhance endothelial cell proliferation and survival. 59 Indeed, we confirmed prostaglandin E2 secretion by stimulated MSC (not shown) and, in addition, we found that MSC release several other anti-inflammatory lipids, such as resolvinD1 and LipoxinA4 (not shown) that may also affect endothelial cell activation and/or proliferation. Another interesting mediator found in the MSC secretome is the soluble form of VCAM-1 (sVCAM-1). High levels of sVCAM-1 have been detected in the synovial fluid of patients with rheumatoid arthritis 60 and in the blood of patients with different types of cancers, 61 but its origin is not entirely clear and our data suggest that MSC may represent an important source of this molecule. Although sVCAM-1 is described as a promoter of angiogenesis, 62 by altering leukocyte trafficking 63 or inhibiting T-cell activation, 64 it may contribute to the MSCinduced suppression of T-cell recruitment that we observed in this study.
The results presented here clearly position endothelial cells as a key target of MSC-mediated immunomodulation during ongoing inflammatory responses and pave the way for developing strategies that exploit MSC-mediated inhibition of lymph-node angiogenesis in the treatment of inflammation-associated pathologies. Furthermore, by identifying TIMP-1 as a critical effector of the anti-inflammatory properties of MSC, this study pinpoints a potential new biomarker in clinical settings. Further studies on the role of TIMP-1 in human MSC are required to confirm its correlation with clinical outcomes or its value in selecting the best source of MSC for immunomodulation. 
